| name | genryzon-drug-interactions |
| description | Drug-interaction and co-medication adjustment reference for a child on Genryzon (somatrogon, weekly long-acting growth hormone). Covers glucocorticoids, insulin and oral hypoglycaemics, thyroxine, oral estrogen, and CYP3A4-metabolised drugs (sex steroids, corticosteroids, anticonvulsants, ciclosporin). Use when a clinician asks about drug interactions with Genryzon or somatrogon, prescribing another drug in a child on GH, girl on Genryzon starting OCP, diabetic child starting GH, adjusting hydrocortisone on GH, or CYP3A4 concerns with somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166). |
Genryzon Drug Interactions
Somatrogon has no direct pharmacokinetic partners, but growth hormone's physiological effects change the requirements for several classes of co-medication. Missing these adjustments causes preventable adverse events.
Step 1 — Screen the medication list at every visit
At every follow-up in a child on Genryzon, review whether they are on any of these classes:
- Glucocorticoids (any dose, any route)
- Insulin or oral hypoglycaemic agents
- Levothyroxine
- Oral estrogen (combined OCP, HRT, isolated estrogen)
- CYP3A4 substrates — sex steroids, systemic corticosteroids, anticonvulsants (esp. phenytoin, carbamazepine, phenobarbital), ciclosporin
Any hit → apply the matching Step 2 rule.
Step 2 — Class-by-class adjustment rules
Glucocorticoids
Effect of GH on the patient:
- GH decreases cortisone → cortisol conversion and may unmask previously undiagnosed central hypoadrenalism
- In an ACTH-deficient child already on hydrocortisone replacement, the same dose may become insufficient on GH
- Concurrent glucocorticoid can inhibit the growth-promoting effect of somatrogon (dose-dependent)
Action:
- Child on hydrocortisone replacement → re-review dose at 4–8 weeks after starting Genryzon; often needs dose ↑ (e.g. from 8 to 10 mg/m²/day). Reinforce sick-day rules and stress dosing
- Child on supraphysiologic glucocorticoid (asthma, IBD, autoimmune) → growth will be blunted; discuss steroid-sparing alternatives with the treating team where possible
- Any child on GH with vague fatigue / abdominal pain / hypotension → low threshold for morning cortisol and stress-dose steroids
- Never stop a glucocorticoid abruptly to "let GH work" — taper properly
Insulin and oral hypoglycaemic agents
Effect of GH:
- GH reduces insulin sensitivity and can precipitate or worsen hyperglycaemia
- Diabetic children on GH usually need more insulin once GH is started
Action:
- T1DM on insulin → expect insulin requirement to ↑ by 10–30% after starting Genryzon. Warn family, adjust rapid- and basal-insulin doses proactively, and increase glucose monitoring frequency during the first month
- T2DM on OADs → similar principle; may need dose ↑ or an additional agent (metformin usually continues; may need SU/DPP-4/other add-on)
- Non-diabetic but at risk → monitor FPG + HbA1c every 3–6 months for the first year, then annually
- Newly diagnosed diabetes on GH → involve paediatric diabetologist; do not stop GH reflexively — most cases are manageable, but the co-morbidity changes the risk-benefit balance
Levothyroxine (thyroxine)
Effect of GH:
- GH increases T4 → T3 conversion
- Can unmask previously undiagnosed central hypothyroidism — free T4 falls, TSH may be normal or inappropriately low
- Can also increase levothyroxine requirement in a child already treated for hypothyroidism
Action:
- Child on levothyroxine → recheck TSH + free T4 at 6–8 weeks after starting Genryzon and at every subsequent 6–12 month visit; titrate levothyroxine up if free T4 has fallen
- Not on levothyroxine, TSH normal at baseline → recheck TSH + fT4 at every visit; be alert for central hypothyroidism (low fT4 with inappropriately normal or low TSH)
- Untreated hypothyroidism blunts the growth response — never leave untreated on GH
Oral estrogen (OCP, HRT)
Effect of oral estrogen:
- Oral estrogen ↑ first-pass hepatic effect → ↓ IGF-1 generation → the child needs a higher somatrogon dose to hit target IGF-1 SDS
- Transdermal estrogen (patch, gel) does not have the same effect — usually no dose adjustment needed
Action:
- Female patient starting oral OCP or HRT → re-check IGF-1 (day 4 post-dose) at 6–8 weeks; expect to need a higher somatrogon dose. See
genryzon-igf1-titration
- Female patient stopping oral estrogen → IGF-1 will rise; expect to reduce somatrogon dose to avoid crossing +2 SDS
- Switching from oral to transdermal → somatrogon requirement will fall; monitor
- In teenage girls on Genryzon, flag OCP status at every visit — it is often the missed cause of an unexpectedly rising or falling IGF-1
CYP3A4-metabolised drugs
Effect of somatrogon:
- Somatrogon induces CYP3A4 mRNA expression in vitro; clinical significance is not fully established
- By analogy with other GH agonists, expect ↑ clearance of CYP3A4 substrates → lower drug levels and potential loss of efficacy
Watch and adjust:
| CYP3A4 substrate class | Practical concern |
|---|
| Sex steroids (estradiol, testosterone) | Potentially reduced levels; check clinical response |
| Systemic corticosteroids (prednisolone, dexamethasone) | Potentially reduced levels; combined with the glucocorticoid effect above, dose review is essential |
| Anticonvulsants (phenytoin, carbamazepine, phenobarbital, valproate) | Check anticonvulsant levels 4–8 weeks after starting Genryzon and after any somatrogon dose change; dose escalation may be needed if levels fall |
| Ciclosporin | Check ciclosporin trough level; adjust to maintain target |
| Other CYP3A4-sensitive drugs (e.g. tacrolimus, sirolimus, some antifungals) | Case-by-case therapeutic drug monitoring |
Action:
- Never assume a stable anticonvulsant or ciclosporin regimen will remain stable on GH. Recheck drug levels
- Loop the specialty team (neurology, transplant, rheumatology) into any planned Genryzon start or dose change
Step 3 — Special situations
Recent tumour or antitumour therapy
Not a drug interaction per se, but relevant to co-medication:
- Somatrogon is contraindicated in active malignancy
- Antitumour therapy must be completed before starting GH
- On-treatment scans and oncologist clearance are prerequisites
Concurrent GH-antagonist drugs
There are no formally listed antagonists in the monograph, but be aware:
- Somatostatin analogues (octreotide, lanreotide) are physiological antagonists of GH — unlikely to be co-prescribed in a child but flag if seen
- Very high-dose glucocorticoid functions as a growth-suppressor — see the glucocorticoid section
Vaccines and infections
- No specific vaccine interaction listed
- Never start Genryzon during acute critical illness or intercurrent respiratory infection (esp. in PWS)
Guardrails
- Adrenal insufficiency can be occult before GH is started — a child on glucocorticoid replacement who becomes unwell after starting Genryzon may need up-titration or stress-dose steroids
- A diabetic child starting GH is going to need more insulin, not less — warn the family up front so they are not surprised by rising glucose
- Central hypothyroidism can be masked by an "acceptable" TSH — always look at free T4 in this context
- Oral vs transdermal estrogen matters — do not treat these as equivalent when planning somatrogon dosing
- Do not assume "no known DDI" means no consequence — the CYP3A4 signal is preclinical, so therapeutic drug monitoring of anticonvulsants, ciclosporin, tacrolimus, and similar is prudent
- Loop specialty teams in early for children on immunosuppressants, anticonvulsants, or complex hormone replacement — dose management is shared care
- Document every adjustment — the reason (drug X was started, IGF-1 SDS changed to Y), the old dose, the new dose, and the recheck plan
Related MD2SKILL skills
genryzon-prescribing-guide — starting dose and monitoring cadencegenryzon-igf1-titration — how oral estrogen changes IGF-1 targets and titrationgenryzon-pretreatment-screening — the baseline checks that determine which of these DDI rules will applygenryzon-red-flag-monitoring — hyperglycaemia / adrenal insufficiency / thyroid symptoms surface here first
Source
Pfizer Products India Pvt. Ltd. GENRYZON® (Somatrogon) Solution for Injection in Pre-filled Pen — Prescribing Information (India). LPD version 2022-0081166 (PfLEET 2022-0081166). Section 4.5 "Drugs Interactions" and Section 4.4 "Special Warnings and Precautions for Use".
